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The purpose of this presentation is 3 fold
and includes the past, present, and future:
L To review the concept of skin-associated
lymphoid tissue (SALT)
2. To summarize the experimental work
related to lymphocyte-keratinocyte reactions in
vitro
3. To briefly outline interferon related the-
rapeutic implications for dermatologists
In the past few years, several review articles
concerning the immunobiology of the skin
have appeared (1-3). The initial skin biologists
were concerned with understanding how the
epidermis could influence and interact with
lymphocytes. Analogies between thymic epithe-
lium and epidermis were made and keratino-
cytes were found to be able to induce terminal
deoxynucleotidyl transferase on T lymphocytes
(4). Next, Chu et al. (5) demonstrated that kera-
tinocytes peroduced a thymopoietin-like mole-
cule which could also induce T-Iymphocyte
differentiation. Most recently, keratinocytes
have been found to produce an Interleukin-l
factor (Epidermal Thymocyte Activating Factor,
ETAF) which can augment the proliferation of
partially stimulated lymphocytes (6, 7). With the
discovery that epidermal Langerhans cells
could function as specialized antigen present-
ing cells to T lymphocytes, there could be little
doubt that the skin was more than a passive
target for various immunologically-mediated
insults, but rather was an active participant in
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the initiation and propagation of such events
(8). Streilein attempted to integrate all these
results into the concept of a skin-associated
lymphoid tissue (SALT) hypothesis in which he
proposed that the immunological microenvir-
onmental endowment of skin served an immu-
nosurveillance function protecting against in-
fectious and neoplastic assaults (2).
The work done at Stanford University during
the past 3 years has attempted to extend the
concept of SALT by focusing not on how kera-
tinocytes influence lymphocytes but on eluci-
dating how lymphocytes may influence kera-
tinocyte growth and differentiation. Our ap-
proach to establishing the proposition of re-
ciprocal keratinocyte-Iymphocyte interactions
in vivo, was to examine the effects of lympho-
cyte produced factors such as interferons
(IFNs) on cultured human keratinocytes.
While interferons were originally described
as antiviral agents (9), they have been found to
affect a wide range of other cellular biologic
functions (10). Interferons are currently clas-
sified into two different groups; types I and II.
Type I IFNs include alpha-interferon, derived
primarily from leukocytes and beta-interferon
derived from fibroblasts and epithelial cells.
Gamma interferon is a Type II interferon
which is produced by activated T lymphocytes.
Utilizing recombinant alpha, beta and
gamma interferons both alone and in combi-
nation, we have made the following observa-
tions:
1. Recombinant gamma interferon (r-IFN-
y) induces the synthesis and expression of
HLA-DR and other triton soluble proteins on
cultured human keratinocytes (11-13).
2. R-IFN-a and r-IFN-y inhibit the growth
of keratinocytes in a concentration dependent
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fashion (14).
3. R-IFN-y induces ultrastructural changes
in keratinocytes suggesting an influence on
differentiation (15).
4. R-IFN-a, {3, y possess antiproliferative
and immunomodulatory activity on a cutane-
ous squamous cell carcinoma in vitro with both
additive and synergistic effects seen combining
type I and II interferons (16).
These results have been recently confirmed
by others (17-19). Most recently, we have
undertaken studies to examine the possible
immunobiological consequences of keratino-
cyte HLA-DR expression (20).
To investigate the significance of HLA-DR
expression by cultured keratinocytes, we ini-
tially asked whether this class II antigen would
be recognized by allogeneic peripheral blood
mononuclear leukocytes (PBMLs). Compared
to HLA-DR positive Langerhans cells (LCs), the
DR+ keratinocytes were relatively weak stimu-
lators of resting T lymphocyte proliferation
(21). While the allogeneic PBMLs apparently
recognized allo-antigen on the keratinocytes by
increasing in size, and RNA synthesis, initial
activation was not followed by proliferation or
\
mitogenesis as determined by 3H-thymidine
incorporation or cell number (ibid). A partial
explanation for this "block" in T lymphocyte
proliferation may have resulted from the in-
creased production by the keratinocytes of
PGE2 by gamma interferon, although other
keratinocyte derived inhibitory factors may be
important in this reaction. These results also
may signify that only dendritic HLA-DR posi-
tive cells such as LCs are capable ofpromoting
resting T lymphocyte proliferation (22). When
the resting T lymphocytes are indubated with
HLA-DR positive keratinocytes in the presence
of interleukin-2 (IL-2) a much greater prolifera-
tive response is observed. Thus in vivo, after
initial activation by LCs, the PBMLs may con-
tinue to interact in biologically important ways
with HLA-DR positive keratinocytes.
Since HLA-DR expression on keratinocytes
is a common feature of 50 or more different
dermatoses, it is important that more work be
done on characterizing lymphocyte-keratino-
cyte interactions (23). D. Krueger and co-
workers have suggested that HLA-DR positive
keratinocytes may influence LC migration into
the skin in vivo (24). Also, it has been suggested
that HLA-DR positive keratinocytes may be tar-
geted for T-cell mediated cytotoxicity in various
lichenoid tissue reactions (25). Another impor-
tant area of research in studies of the role of
interferons in dermatology involves the antivi-
ral rather than the immunomodulatory or
antiproliferative activity of interferons.
By exposing cultured human keratinocytes to
herpes simplex virus (HSV) in vitro, it was pre-
viously observed that interferon production
could be detected (26). Using highly specific
neutralizing antibodies against alpha, beta and
gamma interferon, it has been shown that kera-
tinocytes produce predominantly beta inter-
feron after HSV infection (27). While all three
types of interferon have been found in HSV
vesicle fluid, it was the amount of gamma inter-
feron which was found to correlate with the
recurrence rate (28). Another intriguing recent
observation regarding HSV infections in that a
non PGE2 soluble factor derived from epider-
mal cells co-incubated with HSV antigen was
isolated after UV-B exposure which inhibited
various immunological functions of lympho-
cytes (29). These authors suggest that the pro-
duction of this inhibitory factor after intensive
sun exposure may be responsible for the asso-
ciated occurrence of recurrent herpes labialis.
Finally, what are the possible therapeutic
implications of interferons for dermatology?
With the advent of recombinant biotechnology
the production of highly purified interferons
are widely available for trials. To date, derma-
tologists have taken advantage of the antiviral,
immunomodulatory and antiproliferative ac-
tivities of interferons by utilizing them in the
following diseases (see appendix):
I. Herpes Simplex (30-32)
II. Verruca Plantaris (33, 34)
III. Condyloma Accuminata (33, 35, 36)
IV. Epidermodysplasia Verruciformis (37)
V. Bowenoid Papulosis (38)
VI. Laryngeal Papillomatosis (39)
VII. Leprosy (40)
VIII. Psoriasis (41, 42)
IX. Actinic Keratosis (43)
X. Melanoma (44-46)
XI. Mycosis Fungoides (47)
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It appears that intralesional or systemic ad-
ministration is superior to topical application
of interferon for these diseases and that inter-
ferons are more efficacious as anti-viral agents
than antiproliferative agents at this time. I
believe in the future, therapeutic protocols will
involve combinations of type I and II interfer-
ons and addition of other factors such as IL-2,
tumor necrosis factor, etc. Topical preparations
combining interferons with surfactant-like
molecules to increase epidermal permeation of
the interferons, such as Nonoxynol 9 may be
more efficacious than interferons alone (48).
Much has been learned in the past several
years regarding lymphocyte-keratinocyte inter-
actions and many additional therapeutic trials
using interferons have been published since
the review article by Yancey and Smith in 1980
(49). Considerable work remains ahead both in
the laboratory and in the development of new
1. Herpes Infections
therapeutic strategies utilizing interferon lI1
dermatology (50, 51).
-Appendix-
Summary ofClinical Trials Using
Interferon in Dermatology
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I. Herpes Infections
II. Verruca Plantaris
III. Condyloma Accuminata
IV. Epidermodysplasia Verruciformis
V. Bowenoid Papulosis
VI. Laryngeal Papillomatosis
VII. Leprosy
VIII. Psoriasis
IX. Actinic Keratosis
X. Melanoma
XI. Mycosis Fungoides
Disease Type Interferon* Results Investigator
Merigan et al., 1978
Pazin et al., 1979
Arvin et aI., 1978
Shalev et al., 1984
Non-recombinant
alpha
Non-recombinant
alpha
A. Recurrent herpes
labialis after surgery
trigeminal neuralgia
B. Herpes zoster in
cancer patients
Reduced viral shedding
from 42-9% and reacti-
vation from 83-47%
Limited cutaneous
spread, progression
in primary dermatome and
visceral complications
C. Varicella in Non-recombinant Decreased life-
childhood malignancy alpha threatening dissemination
D. Cutaneous herpes Non-recombinant Complete and rapid
simplex virus alpha healing of skin lesions
*Unless otherwise specified, all interferons were administered intramuscularly for systemic effects.
II. Human Papillomavirus Infections
Disease Type Interferon Results Investigator
A. Verruca Plantaris
(HPV 1, 2)
B. Verruca Vulgaris
C. Condylomata Accuminata
(HPV6,l1)
Recombinant alpha-2
Intralesional
Non-recombinant
beta
Intralesional
Recombinant
alpha-2
Intralesional
Recombinant
alpha-2c
Non-recombinant
beta
No benefit
Good response
in 81% versus
17%placebo
Complete clearing
in 53% versus
14%placebo
Objective response
in 72%
Good response in 82%
versus 9% placebo
Vance et al., 1986
Niimura, 1983
Vance et al., 1986
Gross et aI., 1986
Schonfeld et al., 1984
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D. Bowenoid Papulosis Recombinant Complete response in Gross et aI., 1986
(HPV 16) alpha-2c 1 patient and partial
clearing in 2 others
E. Epidermodysplasia Non-recombinant 75-80% of patients Androphy et al., 1983
Verruciformis alpha, systemic with regression
(HPV 3,5,8) and Intralesional
F. Juvenille Laryngeal Non-recombinant Tumor control in Haylund et al., 1981
Papillomatosis alpha all cases
(HOP 11)
III. Leprosy
Disease Type Interferon Results Investigator
A. Lepromatous Leprosy Recombinant gamma Augmentation of Nathan et aI., 1986
intralesional Monocyte H 20 2
release
Disease Type Interferon Results Investigator
IV. Psoriasis Vulgaris Recombinant gamma Slight benefit Morhenn et aI., 1987
at highest dose
range
Recombinant alpha Exacerbation Quesada et al., 1986
Disease Type Interferon Results Investigator
V. Actinic Keratosis Recombinant alpha 14 of 15 lesions Edwards et al., 1986
cleared after 6
injections
VI. Melanoma
Disease Type Interferon Results Investigator
A. Metastatic Melanoma Non-recombinant 5 of 20 patients Odgren et aI., 1983
alpha plus with complete regression
cimetidine of cutaneous/
subcutaneous lesions
B. Disseminated Melanoma Recombinant a1pha-A 20% objective Creagan et aI., 1984
partial regression
C. Metastatic Melanoma Recombinant alpha-2 25% objective Kirkwood et aI., 1985
partial or complete
response
VII. Cutaneous T-cell Lymphoma
Disease Type Interferon Results Investigator
A. Mycosis Fungoides Recombinant alpha-A 9 of 20 patients Bunn et al., 1984
and with objective
Sezary Syndrome partial remission
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